We are live on ! Find out more
TTNP

Titan Pharmaceuticals
TTNP

Delisted

TTNP was delisted on the 1st of October, 2025.

Back to rankings

19 hedge funds and large institutions have $374K invested in Titan Pharmaceuticals in 2022 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 1 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

600% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 1

33% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 3

6% more funds holding

Funds holding: 18 → 19 (+1)

0.29% less ownership

Funds ownership: 0.54% → 0.25% (-0.29%)

70% less capital invested

Capital invested by funds: $1.24M → $374K (-$869K)

Holders
19
Holders Change
+1
Holders Change %
+5.56%
% of All Funds
0.32%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
7
Reduced
1
Closed
3
Calls
$6K
Puts
–
Net Calls
+$6K
Net Calls Change
-$7K

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$127K
2
VF
Virtu Financial
New York
+$38.9K
3
Millennium Management
Millennium Management
New York
+$33K
4
HF
HRT Financial
New York
+$32.5K
5
UBS Group
UBS Group
Switzerland
+$12.4K

Top Sellers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
-$826K
2
Vanguard Group
Vanguard Group
Pennsylvania
-$82K
3
Barclays
Barclays
United Kingdom
-$48K
4
TRCT
Tower Research Capital (TRC)
New York
-$10K
Name Holding Trade Value Shares
Change 		Change in
Stake
Renaissance Technologies
1
Renaissance Technologies
New York
$135K +$127K +10,210 +559%
Vanguard Group
2
Vanguard Group
Pennsylvania
$42K -$82K -6,576 -64%
Millennium Management
3
Millennium Management
New York
$35K +$33K +2,643 +516%
VF
4
Virtu Financial
New York
$35K +$38.9K +3,117 New
Geode Capital Management
5
Geode Capital Management
Massachusetts
$34K +$5.8K +465 +18%
Group One Trading
6
Group One Trading
Illinois
$33K +$374 +30 +1%
HF
7
HRT Financial
New York
$29K +$32.5K +2,605 New
UBS Group
8
UBS Group
Switzerland
$15K +$12.4K +991 +278%
E
9
Ergoteles
New York
$11K +$11.8K +949 New
IA
10
IFP Advisors
Florida
$3K – – –
LFA
11
Level Financial Advisors
New York
$1K – – –
Citigroup
12
Citigroup
New York
$1K +$1.1K +88 New
APA
13
American Portfolios Advisors
New York
$13 – – –
AC
14
Armistice Capital
New York
– -$826K -43,176 Closed
Barclays
15
Barclays
United Kingdom
– -$48K -2,503 Closed
TRCT
16
Tower Research Capital (TRC)
New York
– -$10K -502 Closed
Wells Fargo
17
Wells Fargo
California
– +$12 +1 +33%
Simplex Trading
18
Simplex Trading
Illinois
– +$75 +6 +33%

TTNP Hedge Fund Activity: Q2 2022 in Review

19 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Titan Pharmaceuticals (TTNP) for Q2 2022, worth a combined $374K — down 70% from $1.24M a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new TTNP positions and 3 closed out — a net gain of 1 holder — while 7 added to existing stakes and 1 trimmed.

The largest buyer was Renaissance Technologies, adding an estimated $127K. The largest seller was Armistice Capital, exiting entirely with an estimated $826K sold.

  • 19 institutional investors held Titan Pharmaceuticals (TTNP) as of Q2 2022, up from 18 in Q1 2022.
  • Funds reported $374K of Titan Pharmaceuticals stock for Q2 2022, down 70% quarter-over-quarter.
  • 4 funds opened new Titan Pharmaceuticals positions in Q2 2022 and 3 closed out, a net change of +1 holder.
  • The largest Titan Pharmaceuticals buyer in Q2 2022 was Renaissance Technologies, an estimated $127K added.
  • The largest Titan Pharmaceuticals seller in Q2 2022 was Armistice Capital, an estimated $826K sold.

Based on aggregated 13F filings for Q2 2022.